Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes-Reference-Cited by-同舟云学术

Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes

Published:2015-09 Issue:3 Volume:66 Page:441-449
ISSN:0272-6386
Container-title:American Journal of Kidney Diseases
language:en
Short-container-title:American Journal of Kidney Diseases

Author:

Cooper Mark E.,Perkovic Vlado,McGill Janet B.,Groop Per-Henrik,Wanner Christoph,Rosenstock Julio,Hehnke Uwe,Woerle Hans-Juergen,von Eynatten Maximilian

Publisher

Elsevier BV

Subject

Nephrology

Reference37 articles.

1. Evolving therapeutic options for type 2 diabetes mellitus: an overview;Guthrie;Postgrad Med,2012

2. Standards of medical care in diabetes—2014;American Diabetes Association;Diabetes Care,2012

3. KDOQI clinical practice guideline for diabetes and CKD: 2012 update;Am J Kidney Dis,2012

4. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes;Nissen;N Engl J Med,2007

5. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis;Singh;JAMA,2007

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease;Kidney International;2024-08

2. Emerging role of antidiabetic drugs in cardiorenal protection;Frontiers in Pharmacology;2024-02-06

3. Exploring Triazole Derivatives as DPP IV Inhibitors: Advancing Type II Diabetes Treatment via Molecular Structure Investigation and Pharmacophore Modelling;Chemistry Africa;2024-01-19

4. Factors Correlated to the Renoprotective Effect of Sitagliptin in Patients with Type 2 Diabetes Mellitus: Retrospective Observational Study;Advances in Pharmacological and Pharmaceutical Sciences;2024-01

5. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024;Diabetes Care;2023-12-11